000			04143nam a2200397 i 4500
999			_c393672 _d393672 _x1
001			393672
003			ES-MaUEC
005			20240314174416.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			100301s2000 xxu| o |||| 0|eng d
020			_a9781592590834
024	7		_a10.1385/1592590837 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQR189 _b2000 EB
245	0	0	_aVaccine Adjuvants : _bPreparation Methods and Research Protocols _cedited by Derek T. O'Hagan
250			_a1st edition 2000
264		1	_aTotowa, NJ _bHumana Press _c2000
300			_a1 recurso en línea (X, 342 páginas)
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aMethods in Molecular Medicine _x1940-6037 _v42
505	0		_aAn Overview of Adjuvant Use -- Harmful and Beneficial Activities of Immunological Adjuvants -- Freund's Adjuvants -- Aluminum Compounds as Vaccine Adjuvants -- Poly(Lactide-Coglycolide) Microparticles As Vaccine Adjuvants -- Poly(Methyl Methacrylate) Nanoparticles As Vaccine Adjuvants -- Aqueous Formulation of Adjuvant-Active Nonionic Block Copolymers -- Liposomes As Immunological Adjuvants and Vaccine Carriers -- Immunopotentiating Reconstituted Influenza Virosomes (IRIVs) -- Cochleates for Induction of Mucosal and Systemic Immune Responses -- Virus-like Particles As Vaccine Adjuvants -- The Adjuvant MF59: A 10-Year Perspective Gary Ott, Ramachandran Radhakrishnan, -- Preparation of the Syntex Adjuvant Formulation (SAF, SAF-m, and SAF-1) -- The ISCOM™ Technology -- QS-21 Adjuvant -- MPL® Immunostimulant: Adjuvant Formulations -- Cytokines As Vaccine Adjuvants: The Use of Interleukin-2 -- DNA As an Adjuvant -- Transcutaneous Immunization -- Mutant Heat-Labile Entertoxins As Adjuvants for CTL Induction.
520			_aAdjuvants play a key role in controlling the efficacy of vaccines, through enhancing the immune response to vaccine antigens, including recombinant proteins, protein polysaccharide conjugates, synthetic peptides, or DNA. In Vaccine Adjuvants: Preparation Methods and Research Protocols, Derek T. O'Hagan and a team of expert vaccinologists and pharmacologists thoroughly describe the preparation, characterization, and evaluation of a wide range of alternative vaccine adjuvants for use in preclinical studies. Each chapter carefully reviews a single adjuvant, including suggestions why a specific adjuvant might be preferred for a given antigen, depending on what type of immune response is desired. Alternate adjuvant choices are also presented so that researchers can choose those most efficacious for their specific purpose. The methods, described in full detail, range from the simple mixing of an antigen with a preformed adjuvant, to a complex preparation process requiring the antigens to be physically associated, or entrapped within, an adjuvant formulation. Comprehensive and highly practical, Vaccine Adjuvants: Preparation Methods and Research Protocols provides an effective guide to making and using vaccine adjuvants. By closely following directions from the book, today's researchers will be able optimally to induce specific immune responses against different types of antigens and to selectively manipulate the immune response in a favorable way. The use of the information in this book will promote the development of powerful new vaccines against infectious diseases and cancers, and may promote the development of products to ameliorate autoimmune disorders.
988			_aSpringer_Protocols_2000
650		7	_2embne _9140409 _aVacunas _vManuales de laboratorio
776	0	8	_iPrinted edition: _z9781617371592
776	0	8	_iPrinted edition: _z9780896037359
776	0	8	_iPrinted edition: _z9781489941848
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1385/1592590837 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b01/2024 _dz _eb _zSI